Cardium Therapeutics Inc. announced a distribution agreement with Academy Medical, LLC to market, sell and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals. Excellagen is FDA-cleared, to support advanced wound care in a broad range of dermal wounds. Academy Medical's initial focus will be to provide education and training on the use of Excellagen in the treatment of traumatic wounds, non-healing venous, pressure and diabetic ulcers, limb salvage, and post-Mohs skin cancer surgery and to support distribution within its growing customer base of over 35 VA and military hospitals within the U.S.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 64 | |
+32.45% | 49.46B | |
+1.57% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.78% | 26.61B | |
-22.65% | 18.64B | |
+7.93% | 13.16B | |
+30.33% | 12.55B | |
+24.13% | 12.1B |
- Stock Market
- Equities
- CRXM Stock
- News Gene Biotherapeutics, Inc.
- Cardium Therapeutics Inc. Announces Sales and Distribution Agreement with Academy Medical, LLC